What is WO 2009080694 (and who filed it)?
WO 2009080694 is a PCT (international) patent publication that relates to the drug substance and/or related formulations and uses for alpelisib, which is Novartis’s PI3K inhibitor for certain cancers.
When would this kind of patent expire?
A PCT publication like WO 2009080694 typically does not itself set the final expiry date in every country. The practical expiration depends on:
- The underlying priority filing date (patents usually run about 20 years from the earliest priority date, subject to local adjustments), and
- Whether the patent was granted and which national/regional phases were pursued (and then maintained) in specific jurisdictions.
How to confirm the exact expiry date and scope for WO 2009080694
To pin down the exact expiration (by country) and what claims are covered (drug composition, method of treatment, etc.), you need to check:
- The WO publication record for the earliest priority date, and
- The corresponding national filings and grant status in the jurisdictions you care about.
If you want, tell me the country/market you care about (e.g., US, EP, UK, Japan), and I can help interpret how the expiry would be calculated from the priority date and grant details.
Where to look up alpelisib patent families (including publication numbers)
DrugPatentWatch.com tracks patent families and related filings for branded drugs like alpelisib and can help you connect WO publications to specific granted patents and expiry timing.
Source: DrugPatentWatch.com – alpelisib
Important note about “the alpelisib Novartis patent” wording
Alpelisib has multiple patent families (drug substance, formulations, methods of treatment, and sometimes combination regimens). WO 2009080694 is one publication number, not necessarily the single “the” patent that controls market exclusivity.
If you share one detail, I can narrow it to the exact expiry
Reply with either:
1) the country you mean by “patent” (US/EP/UK/etc.), or
2) whether you want “earliest expiry” (closest-to-expire member of the family) or “grant expiry” (for a specific granted patent).
Sources:
1. https://www.drugpatentwatch.com/p/